Cannabinoids In Neurodegenerative Disorders And Stroke/Brain Trauma: From Preclinical Models To Clinical Applications

Key Findings:  The studies reviewed here are all concordant with the view that cannabinoid-based medicines may serve as a novel therapy able to delay/arrest neurodegeneration in acute and chronic neurodegenerative conditions, owing to their capability of normalizing glutamate homeostasis, reducing oxidative injury, and/or attenuating local inflammatory events, and possibly also by their capability of activating cellular responses (e.g., induction of autophagy) in controlling the toxicity of protein aggregates, although this has not been addressed here.

Type of Study:  Meta-analysis

Study Result:  Positive

Cannabinoids Studied:  Cannabinoid (unspecified)

Phytocannabinoid Source:  Not Applicable

Form of Administration:  Not Applicable

Receptors Studied:  CB1, CB2

Study Location(s):  Spain

Year of Pub:  2015

Link to study